Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.58 |
| ▸ | CCR8 | P51685 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | CCR5 | P51681 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | MMP9 | P14780 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MMP13 | P45452 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377018 | 1.00 | CCR1 (0.58) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL8690798 | 0.75 | CCR1 (0.89) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL11542337 | 0.75 | CCR1 (0.89) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL31549890 | 0.75 | CCR1 (0.89) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL1232224 | 0.75 | CCR1 (0.89) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL29367277 | 0.75 | CCR1 (1.00) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL29354015 | 0.75 | CCR1 (1.00) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL8312 | 0.75 | CCR1 (1.00) | CCR1CCR8LMNACCR5CYP3A4 | |
| Phenanthroline SCHEMBL8845760 | 0.75 | CCR1 (1.00) | CCR1CCR8LMNACCR5CYP3A4 | |
| SCHEMBL692866 | 0.74 | MMP2 (0.61) | CCR1CCR8LMNACCR5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2000051609-A1 | 3-ALKYL SUBSTITUTED PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051610-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-1009405-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2000-06-21 | — | — | EP | disclosed |
| WO-1999009984-A1 | PYRROLIDINE AND PIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1998025617-A1 | SUBSTITUTED ARYL PIPERAZINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0783498-A4 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO INC (US) | 1998-04-15 | — | — | EP | disclosed |
| EP-0783498-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO. INC. (US) | 1997-07-16 | — | — | EP | disclosed |
| US-5607936-A | USEFUL IN TREATMENT OF RESPIRATORY DISEASES | MERCK & CO., INC. (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996010568-A1 | SUBSTITUTED ARYL PIPERAZINES AS NEUROKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1996-04-11 | — | — | WO | disclosed |
| US-4176183-A | Novel naphthyridines | MERCK & CO., INC. (US) | 1979-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | CCR1 1876/4885CCR8 2970/4885LMNA 2433/4885 |
| US-20250221988-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GSS, G6PC1 | CCR1 4095/4885CCR8 4739/4885LMNA 3243/4885 |
| US-12018015-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CCR1 74/4885CCR8 230/4885LMNA 2102/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | CCR1 1876/4885CCR8 2970/4885LMNA 2433/4885 |
| US-12534450-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | CCR1 10/4885CCR8 57/4885LMNA 1610/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | CCR1 4145/4885CCR8 4162/4885LMNA 1281/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | CCR1 2326/4885CCR8 3124/4885LMNA 2841/4885 |
| US-20240376078-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | CCR1 74/4885CCR8 230/4885LMNA 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.